Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOCUS trial of fosbretabulin added to chemotherapy plus bevacizumab in platinum-resistant recurrent ovarian cancer
2016-001755-45Phase 2Completed
- Sponsor
- Oncotelic Therapeutics, Inc.
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing PCC + bevacizumab + fosbretabulin with PCC + bevacizumab + placebo (2 arms). Primary endpoint: Progression-free survival. Started Jul 2016; status: completed.
02
Drugs
fosbretabulin
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2016-001755-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001755-45.